Union therapeutics stock

Investor Relations – UNION Therapeutics

UNION has raised funds through non-dilutive sources, the European Investment Bank as well as through equity. Key shareholders are founders, management, family …

UNION Therapeutics

UNION is a pharmaceutical development company with a diversified pipeline addressing major unmet medical needs in immunology and infectious diseases.

UNION is a pharmaceutical development company with a diversified pipeline addressing major unmet medical needs in immunology and infectious diseases. UNION was founded in 2011 and is located in Denmark.

Union Therapeutics A/S – Company Profile and News

Company profile page for Union Therapeutics A/S including stock price, company news, press releases, executives, board members, and contact information.

Union Therapeutics Company Profile: Valuation & Investors

Union Therapeutics Company Profile: Valuation & Investors | PitchBook

Information on valuation, funding, cap tables, investors, and executives for Union Therapeutics. Use the PitchBook Platform to explore the full profile.

UNION therapeutics announces full-year results for 2022 and …

UNION therapeutics announces full-year results for 2022 and provides business update | Inderes: Osakeanalyysit, mallisalkku, osakevertailu & aamukatsaus

for 5 dage siden — Morten Boesen, Chief Financial Officer of UNION therapeutics adds: “I am pleased to announce our full-year results for 2022. The investments in …

Hellerup, Denmark, February 9, 2023, – UNION therapeutics A/S (“UNION”), a privately held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious disease, announces full-year results for the period January 1 to December 31, 2022.2022 has been a year of great progress for UNION with several important achievements paving the way for

Union Therapeutics A/S – 33963750 – Hellerup – Proff

Union Therapeutics A/S – 33963750 – Hellerup – Se Regnskaber, Roller og mere

Proff.dk giver dig firmainformation om Union Therapeutics A/S, 33963750. Find vejbeskrivelse, kontaktinfo, regnskabstal, ledelse, bestyrelse og ejere.

FDA fast-tracks Union Therapeutics drug for rare skin disease

FDA fast-tracks Union Therapeutics drug for rare skin disease — MedWatch

11. jan. 2023 — Leo also received Union stock worth DKK 15m (USD 2.2m). Spearheading Union is Kim Kjøller, who worked at Leo Pharma as head of research and …

The US health authority has spotted the opportunity address an unmet medical need by expediting the Danish company’s drug candidate for hidradenitis suppurativa.

UNION therapeutics A/S enters option agreement to acquire …

UNION therapeutics A/S enters option agreement to acquire worldwide exclusive license for COVID-19 technologies developed by TFF Pharmaceuticals, Inc. | Markets Insider

13. aug. 2020 — HELLERUP, Denmark, Aug. 13, 2020 /PRNewswire/ –Niclosamide identified as a potent inhibitor of SARS-Cov-2 by Institut Pasteur Korea, …

HELLERUP, Denmark, Aug. 13, 2020 /PRNewswire/ –Niclosamide identified as a potent inhibitor of SARS-Cov-2 by Institut Pasteur Korea, with potency…

UNION therapeutics receives FDA Fast Track designation for …

UNION therapeutics receives FDA Fast Track designation for oral orismilast for the treatment of moderate to severe hidradenitis suppurativa

10. jan. 2023 — HELLERUP, Denmark, Jan. 10, 2023 /PRNewswire/ — UNION therapeutics A/S (UNION), a privately-held, multi-asset, clinical stage, pharmaceutical …

FDA’s Fast Track designation for oral orismilast underscores the urgent need for new treatment options to fulfil the unmet medical need for people affected by…

UNION therapeutics AS – Annual Report 2020 – Paqle

UNION therapeutics AS – Annual Report 2020

31. dec. 2020 — UNION therapeutics A/S (in the following “the Company” or “UNION”) is a … As UNION therapeutics A/S is not listed on a stock exchange the …